



**ENFORCE**

**Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines**

**Monthly Report**

Report number: 6

Date Report: 1<sup>st</sup> December 2021

Date of data extract: 30<sup>th</sup> November 2021

Report prepared by: the ENFORCE consortium

Approved by: the ENFORCE scientific steering committee

This report is an edited version of the confidential report generated for distribution and review to the Danish Medicines Agency only. Tables and figures with small numbers (<5 participants per cell) or very specific details and where there is the potential that individual participants could be identified or be able to identify themselves have been removed or edited to maintain participant confidentiality.

## Contents

Summary of key changes from previous report .....	3
Enrolment .....	3
Outcomes .....	3
Safety and Monitoring .....	3
Methods .....	4
Data sources .....	4
Definitions .....	4
Enrolment .....	5
Demographics at enrolment .....	7
Enrolment Progress .....	8
Third dose progress .....	10
Withdrawal/Loss to follow-up .....	12
Outcomes .....	13
Primary outcome .....	13
Primary outcome among those who have received a third dose .....	20
Secondary outcome .....	24
Safety Monitoring .....	25
Local and systemic reactions .....	25
Adverse and Serious Adverse Events .....	32
Deaths .....	33

## Summary of key changes from previous report

### Enrolment

Information on the number of individuals who have received a third (booster) dose and the timing relative to the first vaccination date is now included.

### Outcomes

The results of the serum antibody quantification using ELISA (Wantai) performed by Statens Serum Institut (SSI) and from the multiantigen serological tests for antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid are included for those with data up to visit 4 (six months after first vaccination). Results are also shown for those who have received a third dose and had a study visit within 14 days prior to their third vaccination or 28 days following.

The number of breakthrough infections as assessed by a positive SARS-CoV-2 PCR test result after receiving a first dose of vaccine is also included. We are working on incorporating the Nucleocapsid data into this measure.

### Safety and Monitoring

Tables summarizing any symptoms reported following the first, second and third dose of the vaccine are included in the report, overall and by vaccine type. Figures showing the severity of the symptoms are also included for all three doses, stratified by vaccine. In previous reports, figures summarizing the severity of symptoms by the age and sex of participants for the first and second dose of each vaccine were also provided. These have been removed from this report as all data on this has been collected and included in the last report.

Serious adverse events (SAE) and adverse events (AE) (grade 3 & 4) now also include those reported following the third vaccine dose.

## Methods

The data presented in this report are descriptive. A detailed statistical analysis plan will be developed prior to any formal analysis being conducted.

### Data sources

The data used to generate this report are currently based on the data stored in REDCap from the case report forms (CRFs) and online symptoms form. Data on serum antibody quantification using ELISA (Wantai) was provided by the SSI and the multiantigen serological tests by Aarhus University Hospital.

Information on the type of vaccines received and the dates of vaccinations were initially collected and reported through the study CRFs. This has now been validated via data from the Danish Vaccine Register (DDV), with the DDV considered the gold standard where discrepancies have arisen.

Data on any SARS-CoV-2 PCR-tests or SARS-CoV-2 antibody measurements were extracted from the surveillance system Key Infectious Diseases System (KIDS).

Data on deaths are reported from two sources, as a serious adverse events (SAE) on the CRF and recorded in REDCap or through the Danish Civil Registration System (CPR). The CPR registry is a national register containing basic patient information, including dates of the deaths for all persons in Denmark who have a CPR number.

### Definitions

In this version of the report the type of vaccine received, and date of vaccination is predominately based on information provided from the DDV. However, for individuals newly enrolled in the study and where information from the DDV is not yet available the type of vaccine received is based on self-reports from participants at enrolment into the study, prior to them receiving their first vaccine.

Results from the ELISA detection of total serum Ig to the Receptor Binding Domain (Wantai) were recorded as Negative (ratio <0.9), Positive (ratio >1.1), or inconclusive (ratio between 0.9-1.1). The ratio was calculated as the OD value/cut-off, where the cut-off= average of the negative controls +0.16. If the average is below 0.03 then the cut-off is set to 0.16 + 0.03. For manual execution the cut-off will almost always be 0.19.

For the multiantigen serological tests, the geometric mean and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid at each study visit are reported. The calibration curve used to calculate antibody concentrations are performed by fitting the signals from the calibrators in a 4-parameter sigmoidal dose-response model. Antibody concentrations can then be determined from their ECL signals by backfitting to the calibration curve.

Breakthrough infection was defined as a positive SARS-CoV-2 PCR test result reported in the KIDS dataset after the date of first vaccination. The timing of the infection was based on the date of first positive test.

## Enrolment

The section gives an overview of the current enrolment status of participants in the study. Table 1 outlines the number of participants currently enrolled in the study and reasons for exclusion.

*Table 1 Summary of participants enrolled in the study*


<i>Total included</i>	<i>Reason for exclusion</i>
6950	All patients
6927	Consent withdrawn and requested data deleted
6927	Provided informed consent
6927	Missing enrolment date
6926	Aged under 18
6926	Vaccine not recommended
6926	Vaccinated Previously
6926	Agrees to follow protocol
6926	No DDV vaccine data (consent withdrawn) and expected to receive AZ after 10/3/21
6924	No DDV vaccine data (consent withdrawn) and only one study visit (enrolment)
6924	No DDV vaccine data (consent withdrawn) and no study visit after second vaccine
6915	Non-standard vaccine regimen*

\*Non-standard regimens included AstraZeneca only, the Janssen COVID-19 vaccine, and a combination of Pfizer-BioNTech and Moderna.

Figure 1 shows the cumulative number of participants enrolled by vaccine type. Enrolment began on the 13<sup>th</sup> February 2021 when the first patient was enrolled prior to receiving the AstraZeneca vaccine. The first participant enrolled prior to receiving the Pfizer-BioNTech vaccination was on the 16<sup>th</sup> February 2021, followed by Moderna on the 24<sup>th</sup> February 2021.

Enrolment into the AstraZeneca vaccine group was stopped following the pausing of AstraZeneca vaccination on 11<sup>th</sup> March 2021. Enrolment for those receiving Pfizer was paused in week 15, after the target of 2500 participants was reached, but then restarted in week 20. Enrolment in all vaccine groups was completed in August 2021.

Figure 1 Cumulative number of participants enrolled by vaccine type



## Demographics at enrolment

Table 2 gives an overview of the participant demographics at the time of enrolment into the study overall and by vaccine. Table 3 gives an overview of the number of participants with concomitant diseases at enrolment and the use of any medications in the 24 hours prior to enrolment.

Table 2 Participant demographics at study enrolment by vaccine

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Gender					
Male	2999 (43.4)	1841 (48.1)	1084 (41.4)	58 (14.9)	16 (19.0)
Female	3916 (56.6)	1983 (51.9)	1535 (58.6)	330 (85.1)	68 (81.0)
Median (interquartile range, IQR)					
Age at enrolment (years)	64 (54, 75)	71 (55, 78)	61 (54, 69)	45 (31, 56)	46 (34, 56)
Enrolment date	APR21 (MAR21, MAY21)	MAR21 (MAR21, APR21)	MAY21 (APR21, MAY21)	MAR21 (FEB21, MAR21)	MAR21 (FEB21, MAR21)

Table 3 Concomitant diseases and medications, overall and by vaccine

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Any concomitant disease N (%)	4548 (65.8)	2832 (74.1)	1556 (59.4)	146 (37.6)	14 (16.7)
Any medications taken in the last 24 hours N (%)	4778 (69.1)	2956 (77.3)	1605 (61.3)	182 (46.9)	35 (41.7)

### Enrolment Progress

Figure 2 shows the current status of participants in the study at the date of most recent data extract. Participants have been in the study from between 4 and 10 months. Table 4 gives the number of participants included in the study who have received each dose of the vaccine and also the number and percentage who have completed each study visit.

Figure 2 Current status of participants






Table 4 Number and percentage of participants completing each study visit

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca /Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Received two doses (N, %)	6905 (99.9)	3817 (99.8)	2616 (99.9)	388 (100)	84 (100)
Time between first and second dose (median, IQR)	29 (22, 35)	23 (21, 28)	35 (35, 36)	83 (79, 87)	82 (79, 87)
Visit 2 (prior to second vaccination) (N, %)	6530 (94.4)	3635 (95.1)	2517 (96.1)	328 (84.5)	50 (59.5)
Days from first vaccine to second study visit (median, IQR)	28 (21, 35)	22 (21, 27)	34 (32, 35)	83 (79, 89)	82 (77, 87)
Visit 3 (3 months after first vaccination) (N, %)	6003 (86.8)	3444 (90.1)	2475 (94.5)	64 (16.5)	20 (23.8)
Days from first vaccine to third study visit (median, IQR)	91 (89, 96)	91 (89, 95)	92 (89, 96)	96 (90, 101)	97 (92, 99)
Visit 4 (6 months after first vaccination) (N, %)	5251 (75.9)	3043 (79.6)	1842 (70.3)	309 (79.6)	57 (67.9)
Days from first vaccine to fourth study visit (median, IQR)	182 (178, 185)	182 (179, 185)	182 (177, 185)	182 (179, 186)	182 (180, 189)


### Third dose progress

Table 5 gives the number of participants included in the study who have received a third dose of the vaccine and the number and percentage who have completed each booster visit among those who have received a third dose. Figure 3 show the proportion of participants in each vaccine group who have received a third dose.

Table 5 Number and percentage of participants completing study visits related to their third does

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca /Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Received a third dose (N, %)	2653 (38.4)	2352 (61.5)	45 (1.7)	215 (55.4)	41 (48.8)
Time between first and third dose (median, IQR)	230 (224, 237)	229 (223, 235)	206 (193, 218)	250 (237, 260)	245 (231, 266)
Visit X (0-14 days prior to third dose) (N, %)	939 (35.4)	811 (34.5)	16 (35.6)	93 (43.3)	19 (46.3)
Visit X used as pre-booster visit	832 (31.4)	719 (30.6)	3 (6.7)	91 (42.3)	19 (46.3)
Visit 4 used as pre-booster visit	107 (4.0)	92 (3.9)	13 (28.9)	2 (0.9)	0
Days from pre-booster visit to third dose (median, IQR)	2 (0, 5)	2 (0, 5)	9 (5, 12)	2 (0, 5)	1 (0, 4)
Visit Xc (28 days after third dose) (N, %)	545 (20.5)	450 (19.1)	28 (62.2)	57 (26.5)	10 (24.4)
Days from third dose to post-booster visit (median, IQR)	28 (25, 30)	28 (26, 31)	29 (27, 31)	23 (21, 27)	29 (25, 32)

Figure 3 Percentage of participant receiving a third dose by calendar month



### Withdrawal/Loss to follow-up

Table 6 shows the number of participants enrolled in the study who have subsequently withdrawn and no longer wish to be contacted or attend future study visits.

*Table 6 Number and percent of participants discontinuing in the study, by vaccine type*

	Vaccine type				
	<i>Total</i> (N=6915)	<i>Pfizer- BioNTech</i> (N=3824)	<i>Moderna</i> (N=2619)	<i>AstraZeneca/ Pfizer</i> (N=388)	<i>AstraZeneca/ Moderna</i> (N=84)
Study status (N, % of total)					
Still under follow-up	6522 (94.3)	3544 (92.7)	2569 (98.1)	339 (87.4)	70 (83.3)
Total withdrawn (N, % of total)	393 (5.7)	280 (7.3)	50 (1.9)	49 (12.6)	14 (16.7)

## Outcomes

### Primary outcome

Until the threshold for MPNAT has been established we will present the results from both the ELISA (Wantai) and the multiantigen serological test including the Receptor Binding Domain (RBD), and the complete Spike (S) protein and the Nucleocapsid (NC).

The data from the ELISA (Wantai) are presented as negative, positive and inconclusive (see methods for categorization) and are shown in Figure 4 and the numbers included at each time point in Table 7.

Figure 4 Presence of antibodies at study visit, ELISA (Wantai) from SSI




Table 7 Number of individuals with antibody data at each study visit, ELISA (Wantai) from SSI

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
SSI antibody data at visit 1 (enrolment) (N, % of total)	6867 (99.3)	3791 (99.1)	2613 (99.8)	381 (98.2)	82 (97.6)
SSI antibody data at visit 2 (prior to second vaccination) (N, % of total)	6369 (92.1)	3580 (93.6)	2492 (95.2)	259 (66.8)	38 (45.2)
Days from first vaccination (median (IQR))	28 (21, 35)	22 (21, 27)	34 (32, 35)	82 (78, 85)	82 (77, 87)
SSI antibody data at visit 3 (3 months after first vaccination) (N, % of total)	5956 (86.1)	3412 (89.2)	2460 (93.9)	64 (16.5)	20 (23.8)
Days from first vaccination (median (IQR))	91 (89, 96)	91 (89, 95)	92 (89, 96)	96 (90, 101)	97 (92, 99)
SSI antibody data at visit 4 (6 months after first vaccination) (N, % of total)	4922 (71.2)	2829 (74.0)	1731 (66.1)	305 (78.6)	57 (67.9)
Days from first vaccination (median (IQR))	182 (178, 185)	182 (179, 185)	182 (177, 185)	182 (179, 186)	182 (180, 189)

From the multiantigen serological tests, the geometric mean (GM) and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid at each study visit are reported in Table 8. Figure 5-7 show the distribution of the three assays on the log<sub>10</sub> scale, by vaccine type and study visit.

Table 8 Presence of antibodies at study visit, Receptor-Binding Domain (RBD), Spike antibody and Nucleocapsid

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
AUH antibody data at visit 1 (enrolment) (N, % of total)	6858 (99.2)	3791 (99.1)	2604 (99.4)	381 (98.2)	82 (97.6)
AUH antibody data at visit 2 (prior to second vaccination) (N, % of total)	6360 (92.0)	3575 (93.5)	2490 (95.1)	257 (66.2)	38 (45.2)
AUH antibody data at visit 3 (3 months after first vaccination) (N, % of total)	5952 (86.1)	3410 (89.2)	2458 (93.9)	64 (16.5)	20 (23.8)
AUH antibody data at visit 4 (6 months after first vaccination) (N, % of total)	4283 (61.9)	2711 (70.9)	1214 (46.4)	301 (77.6)	57 (67.9)
<b>CoV-2 Receptor-Binding Domain (SERO)</b>					
GM at enrolment (95%CI)	59 (57, 61)	53 (50, 55)	65 (62, 69)	89 (74, 107)	58 (42, 79)
GM at visit 2 (95%CI)	8809 (8376, 9265)	4086 (3819, 4371)	27498 (25924, 29166)	7017 (5807, 8479)	4063 (2579, 6401)
GM at visit 3 (95%CI)	95243 (91434, 99211)	52055 (49151, 55131)	211754 (203596, 220240)	283372 (235142, 341495)	356061 (274785, 461377)
GM at visit 4 (95%CI)	29932 (28491, 31447)	16926 (15934, 17981)	73348 (68417, 78634)	103214 (92268, 115458)	132483 (102755, 170812)
<b>CoV-2 Spike antibody (SERO)</b>					
GM at enrolment (95%CI)	106 (102, 110)	102 (97, 108)	104 (98, 111)	161 (131, 199)	113 (79, 161)
GM at visit 2 (95%CI)	26725 (25506, 28001)	13665 (12822, 14563)	74112 (70260, 78175)	17299 (14509, 20626)	12156 (7795, 18959)
GM at visit 3 (95%CI)	173322 (167500, 179346)	108438 (103133, 114015)	322655 (313239, 332354)	392880 (350127, 440853)	455735 (407411, 509791)
GM at visit 4 (95%CI)	65369 (62554, 68310)	39763 (37624, 42024)	142561 (134402, 151215)	193480 (176984, 211515)	241303 (201103, 289539)
<b>CoV-2 Nucleocapsid (SERO)</b>					

	<i>Vaccine type</i>				
	<i>Total</i> (N=6915)	<i>Pfizer- BioNTech</i> (N=3824)	<i>Moderna</i> (N=2619)	<i>AstraZeneca/ Pfizer</i> (N=388)	<i>AstraZeneca/ Moderna</i> (N=84)
GM at enrolment (95%CI)	263 (251, 275)	268 (252, 284)	243 (226, 261)	359 (287, 449)	294 (202, 429)
GM at visit 2 (95%CI)	301 (287, 314)	283 (267, 301)	316 (295, 340)	431 (328, 566)	244 (142, 418)
GM at visit 3 (95%CI)	412 (394, 430)	376 (354, 399)	462 (433, 493)	637 (394, 1030)	419 (227, 772)
GM at visit 4 (95%CI)	418 (396, 441)	398 (372, 426)	424 (385, 467)	601 (484, 747)	449 (290, 697)

GM: Geometric mean



Figure 5 Distribution of CoV-2 Receptor-Binding Domain (RBD) levels at each study visit (see Table 8 for the number included at each time point)




Figure 6 Distribution of CoV-2 Spike antibody levels at each study visit (see Table 8 for the number included at each time point)





Figure 7 Distribution of CoV-2 Nucleocapsid levels at each study visit (see Table 8 for the number included at each time point)



Primary outcome among those who have received a third dose

The percentage of participants with results from the ELISA (Wantai) assay within 14 days prior to receiving their third dose and 28 days following the vaccination are shown in Table 9.

Table 9 Presence of antibodies at study visit, ELISA (Wantai) from SSI, among participants who have received a third dose

	Vaccine type				
	Total (N=2653)	Pfizer- BioNTech (N=2352)	Moderna (N=45)	AstraZeneca/P fizer (N=215)	AstraZeneca/ Moderna (N=41)
SSI antibody data 0-14 days before third dose (N, % of total)	922 (34.8)	795 (33.8)	16 (35.6)	92 (42.8)	19 (46.3)
Wantai result prior to booster (visit X)					
Negative	41 (4.4)	40 (5.0)	<5*	0	0
Positive	880 (95.4)	755 (95.0)	14 (87.5)	92 (100)	19 (100)
Inconclusive	<5*	0	<5*	0	0
SSI antibody data 28 days after third dose (N, % of total)	487 (18.4)	402 (17.1)	27 (60.0)	50 (23.3)	8 (19.5)
Wantai result after booster (visit Xc)					
Negative	40 (8.2)	37 (9.2)	<5*	0	0
Positive	444 (91.2)	363 (90.3)	23 (85.2)	50 (100)	8 (100)
Inconclusive	<5*	<5*	<5*	0	0

\*Exact numbers not shown due to small numbers

From the multiantigen serological tests, the geometric mean (GM) and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid at the visit prior to the third dose and 28 days following the third dose are reported in Table 10

**Reference source not found..**

*Table 10 Presence of antibodies at study visit, Receptor-Binding Domain (RBD), Spike antibody and Nucleocapsid, among participants who have received a third dose*

	Vaccine type				
	Total (N=2653)	Pfizer- BioNTech (N=2352)	Moderna (N=45)	AstraZeneca/ Pfizer (N=215)	AstraZeneca/ Moderna (N=41)
AUH antibody data 0-14 days before third dose (N, % of total)	575 (21.7)	478 (20.3)	16 (35.6)	70 (32.6)	11 (26.8)
AUH antibody data 28 days after third dose (N, % of total)	318 (12.0)	266 (11.3)	25 (55.6)	23 (10.7)	<5*
CoV-2 Receptor-Binding Domain (SERO)					
GM 0-14 days before third dose (95%CI)	12606 (10768, 14758)	9653 (8136, 11453)	19791 (5355, 73136)	52910 (40895, 68456)	77533 (39289, 153003)
GM 28 days after third dose (95%CI)	51606 (36768, 72432)	39968 (27443, 58209)	72753 (18324, 288867)	448086 (375146, 535208)	-
CoV-2 Spike antibody (SERO)					
GM 0-14 days before third dose (95%CI)	30614 (26547, 35304)	24353 (20858, 28434)	38560 (10666, 139407)	108837 (86885, 136336)	141970 (78731, 256007)
GM 28 days after third dose (95%CI)	98528 (74880, 129644)	81346 (59834, 110592)	132977 (45257, 390725)	488189 (454857, 523964)	-
CoV-2 Nucleocapsid (SERO)					
GM 0-14 days before third dose (95%CI)	453 (390, 525)	427 (362, 503)	480 (204, 1127)	680 (435, 1063)	402 (137, 1178)
GM 28 days after third dose (95%CI)	530 (443, 634)	487 (402, 589)	569 (305, 1062)	1111 (468, 2637)	-

\*Exact numbers not shown due to small numbers

Figure 8 and Figure 9 show the distribution of the antibody levels against the Receptor Binding Domain, the complete Spike protein on the log<sub>10</sub> scale, at visit 3 (90 days after the first vaccine dose), 0-14 days prior to receiving the third dose and 28 days after receiving the third dose. Only participants with results both prior to the third dose and after the third dose are included. There are currently only 240 participants with results from both visits, so the data are not stratified by vaccine type.

Figure 8 Distribution of CoV-2 Receptor-Binding Domain (RBD) levels among participants who have received a third dose





Figure 9 Distribution of CoV-2 Spike antibody levels among participants who have received a third dose



## Secondary outcome

The secondary outcome of breakthrough infections is monitored in two different ways. The number of participants testing positive for SARS-CoV-2, as reported via KIDS, and by serological monitoring (detection of SARS-CoV-2 nucleocapsid antibodies). The number of participants experiencing a positive PCR test following their first vaccination is reported in Table 11.

Table 11 Number of participants testing positive for SARS-CoV-2

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca /Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Number of PCR tests since first vaccine dose (median, IQR)	2 (0, 5)	2 (0, 4)	2 (1, 5)	11 (6, 16)	9 (3, 13)
Number of antigen tests since first vaccine dose (median, IQR)	1 (0, 3)	1 (0, 3)	2 (0, 4)	3 (0, 6)	5 (1, 9)
Number PCR positive for SARS-CoV-2 reported via KIDS (N, % of total)	125 (1.8)	79 (2.1)	38 (1.5)	8 (2.1)	<5*
Days from first vaccine dose to SARS-CoV2 positive test (median, IQR)	176 (134, 221)	196 (139, 224)	155 (84, 190)	252 (80, 267)	. (., .)

\*Exact numbers not shown due to small numbers



## Safety Monitoring

### Local and systemic reactions

Table 12 outlines the number of participants reporting any local or systemic reactions within 7 days of vaccination. The total number of participants experiencing any symptoms are reported as well as the number experiencing each individual symptom. Note that participants can report multiple symptoms. The percentages are out of the total number of participants who had completed the symptoms form at the time of data extraction. All participants are encouraged to complete the form even if they experience no symptoms. Figure 10 shows the proportion reporting mild, moderate or severe symptoms by vaccine type.

Similarly, Table 13 outlines the number of participants reporting any local or systemic reactions within 0-7 days and 8-14 days of the third vaccine and Figure 11 the proportion reporting mild, moderate or severe symptoms by vaccine type.

Table 12 Number & percent reporting local/systemic reactions within 7 days post vaccination overall, all and by vaccination

	Total		Pfizer-BioNTech		Moderna		AstraZeneca/Pfizer		AstraZeneca/Moderna	
	First (N=6521)	Second (N=6057)	First (N=3595)	Second (N=3380)	First (N=2512)	Second (N=2361)	First (N=349)	Second (N=261)	First (N=65)	Second (N=55)
Number of persons (%)										
Any clinical symptoms	3795 (58.2)	4152 (68.5)	1879 (52.3)	1933 (57.2)	1536 (61.1)	1973 (83.6)	321 (92.0)	197 (75.5)	59 (90.8)	49 (89.1)
Any local symptoms at injection site	5147 (78.9)	4753 (78.5)	2595 (72.2)	2336 (69.1)	2191 (87.2)	2132 (90.3)	305 (87.4)	237 (90.8)	56 (86.2)	48 (87.3)
Symptoms reported										
Muscle pain	1863 (29.1)	2297 (38.9)	842 (23.8)	921 (27.9)	773 (31.4)	1217 (53.4)	208 (60.3)	120 (46.5)	40 (65.6)	39 (70.9)
Joint pain	941 (14.9)	1595 (27.3)	400 (11.4)	590 (18.0)	351 (14.4)	905 (40.1)	161 (48.1)	74 (28.8)	29 (46.8)	26 (49.1)
Fatigue	2663 (41.4)	3397 (57.0)	1299 (36.6)	1533 (46.0)	1041 (42.1)	1661 (71.8)	277 (80.5)	161 (62.2)	46 (74.2)	42 (76.4)
Fever	576 (9.1)	1435 (24.5)	160 (4.6)	355 (10.8)	190 (7.8)	992 (43.5)	189 (55.6)	57 (22.4)	37 (58.7)	31 (57.4)
Headache	1743 (27.3)	2331 (39.4)	756 (21.4)	938 (28.5)	691 (28.1)	1251 (54.4)	248 (71.7)	110 (42.6)	48 (75.0)	32 (58.2)
Nausea	687 (10.9)	1044 (18.0)	268 (7.6)	381 (11.7)	271 (11.2)	605 (27.1)	126 (37.6)	41 (16.1)	22 (35.5)	17 (30.9)
Chills	682 (10.8)	1276 (21.9)	226 (6.5)	370 (11.4)	216 (8.9)	844 (37.5)	200 (58.8)	38 (15.0)	40 (64.5)	24 (44.4)
Local symptoms at injection site										
Redness	619 (9.9)	1015 (17.8)	260 (7.5)	332 (10.3)	290 (12.1)	625 (28.5)	55 (16.7)	41 (16.6)	14 (23.3)	17 (32.7)
Swelling	1055 (17.0)	1417 (25.0)	407 (11.9)	500 (15.6)	552 (23.1)	826 (37.8)	78 (24.0)	74 (30.5)	18 (29.5)	17 (40.5)
Tenderness	5094 (78.6)	4674 (77.8)	2561 (71.8)	2296 (68.5)	2175 (86.9)	2095 (89.5)	303 (87.3)	235 (91.1)	55 (84.6)	48 (87.3)



Table 13 Number & percent reporting local/systemic reactions within 0-7 days and 8-14 days following a third vaccine dose, overall and by vaccination

	Total		Pfizer-BioNTech		Moderna		AstraZeneca/Pfizer		AstraZeneca/Moderna	
	First 7 days (N=887)	8-14 days (N=720)	First 7 days (N=706)	8-14 days (N=570)	First 7 days (N=75)	8-14 days (N=59)	First 7 days (N=90)	8-14 days (N=78)	First 7 days (N=16)	8-14 days (N=13)
Number of persons (%)										
Any clinical symptoms	467 (52.6)	179 (24.9)	346 (49.0)	136 (23.9)	48 (64.0)	21 (35.6)	58 (64.4)	18 (23.1)	15 (93.8)	<5*
Any local symptoms at injection site	644 (72.6)	128 (17.8)	495 (70.1)	102 (17.9)	60 (80.0)	15 (25.4)	73 (81.1)	8 (10.3)	16 (100)	<5*
Symptoms reported										
Muscle pain	225 (25.9)	62 (8.7)	161 (23.1)	55 (9.7)	25 (34.7)	6 (10.3)	25 (29.1)	<5*	14 (87.5)	<5*
Joint pain	147 (17.1)	46 (6.5)	101 (14.7)	40 (7.1)	19 (26.4)	<5*	20 (23.0)	<5*	7 (43.8)	<5*
Fatigue	350 (40.5)	128 (18.0)	250 (36.4)	95 (16.8)	38 (52.8)	16 (27.6)	49 (54.4)	13 (16.7)	13 (81.3)	<5*
Fever	104 (12.1)	24 (3.4)	73 (10.7)	18 (3.2)	11 (15.9)	5 (8.6)	13 (14.8)	<5*	7 (43.8)	<5*
Headache	224 (25.9)	77 (10.8)	157 (22.8)	56 (9.9)	20 (28.2)	8 (14.0)	37 (41.6)	9 (11.5)	10 (62.5)	<5*
Nausea	77 (9.0)	30 (4.2)	59 (8.7)	21 (3.8)	<5*	<5*	9 (10.3)	<5*	5 (31.3)	<5*
Chills	99 (11.6)	28 (3.9)	75 (11.0)	22 (3.9)	13 (18.3)	5 (8.6)	7 (8.0)	<5*	4 (25.0)	<5*
Local symptoms at injection site										
Redness	109 (13.0)	24 (3.4)	76 (11.4)	17 (3.0)	18 (25.4)	5 (8.8)	10 (11.6)	<5*	5 (31.3)	<5*
Swelling	144 (17.2)	32 (4.6)	102 (15.3)	26 (4.7)	22 (31.4)	<5*	15 (17.6)	<5*	5 (31.3)	<5*
Tenderness	631 (72.1)	124 (17.5)	484 (69.5)	100 (17.8)	58 (78.4)	13 (23.2)	73 (82.0)	8 (10.4)	16 (100)	<5*

\*Exact numbers not shown due to small numbers

Figure 10 Percentage of participants reporting systemic and local symptoms within 0-7 days of their 1<sup>st</sup> dose and 2<sup>nd</sup> dose of the vaccine, by vaccine type








Figure 11 Percentage of participants reporting systemic and local symptoms following the 3<sup>rd</sup> dose of the vaccine, by vaccine type





### Adverse and Serious Adverse Events

This section gives an overview of the AEs (Table 14) and SAEs (Table 15) reported in the study thus far. The data are shown overall and by vaccine type.

Table 14 Overview of AEs (grade 3 and 4) reported by vaccine

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Number of persons (%)					
At least one Adverse Event reported	798 (11.5)	401 (10.5)	318 (12.1)	69 (17.8)	10 (11.9)
Number of AE					
1	588 (73.7)	297 (74.1)	234 (73.6)	51 (73.9)	6 (60.0)
2	139 (17.4)	69 (17.2)	54 (17.0)	13 (18.8)	<5*
3	45 (5.6)	25 (6.2)	17 (5.3)	<5*	<5*
>=4	26 (3.3)	10 (2.5)	13 (4.1)	<5*	<5*

\*Exact numbers not shown due to small numbers

Table 15 Overview of SAEs reported by vaccine

	Vaccine type				
	Total (N=6915)	Pfizer- BioNTech (N=3824)	Moderna (N=2619)	AstraZeneca/ Pfizer (N=388)	AstraZeneca/ Moderna (N=84)
Total number of participants reporting any SAE (N, %)	133 (1.9)	100 (2.6)	27 (1.0)	5 (1.3)	<5*
Total number of SAE reported (N, % of SAE)	156 (100)	121 (100)	29 (100)	5 (100)	<5*

\*Exact numbers not shown due to small numbers



## Deaths

There have been eighteen deaths reported in the study thus far. Eight were reported as a SAE but none had a reasonable probability of relatedness to vaccination nor were reported as a SUSAR. There were an additional ten deaths recorded in the CPR registry that were outside of the period for reporting SAE.